Literature DB >> 31811944

Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series.

Richard Paul Ramonell1, F Eun-Hyung Lee1, Colin Swenson1, Merin Kuruvilla2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31811944      PMCID： PMC9161156          DOI： 10.1016/j.jaip.2019.11.031

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis.

Authors:  Matthew C Altman; Jake Lenington; Steve Bronson; Andrew G Ayars
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-06

Review 2.  Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature.

Authors:  Jian-Xiong Li; Li-Chao Fan; Man-Hui Li; Wei-Jun Cao; Jin-Fu Xu
Journal:  Respir Med       Date:  2016-11-26       Impact factor: 3.415

Review 3.  Allergic bronchopulmonary aspergillosis.

Authors:  Paul A Greenberger; Robert K Bush; Jeffrey G Demain; Amber Luong; Raymond G Slavin; Alan P Knutsen
Journal:  J Allergy Clin Immunol Pract       Date:  2014-11-06

4.  Induction of mucin and MUC5AC expression by the protease activity of Aspergillus fumigatus in airway epithelial cells.

Authors:  Tsuyoshi Oguma; Koichiro Asano; Katsuyoshi Tomomatsu; Motohiro Kodama; Koichi Fukunaga; Tetsuya Shiomi; Nao Ohmori; Soichiro Ueda; Takahisa Takihara; Yoshiki Shiraishi; Koichi Sayama; Shizuko Kagawa; Yukikazu Natori; Craig M Lilly; Kazuo Satoh; Koichi Makimura; Akitoshi Ishizaka
Journal:  J Immunol       Date:  2011-06-17       Impact factor: 5.422

5.  Inhibition of IL-13-induced periostin in airway epithelium attenuates cellular protein expression of MUC5AC.

Authors:  Isao Suzaki; Shuichi Kawano; Kosaku Komiya; Tsuyoshi Tanabe; Tomohiro Akaba; Kazuhito Asano; Harumi Suzaki; Kenji Izuhara; Bruce K Rubin
Journal:  Respirology       Date:  2016-08-24       Impact factor: 6.424

6.  Increased sensitivity to IL-4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis.

Authors:  A P Knutsen; P S Hutchinson; G M Albers; J Consolino; J Smick; V P Kurup
Journal:  Allergy       Date:  2004-01       Impact factor: 13.146

7.  A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma.

Authors:  Ritesh Agarwal; Sahajal Dhooria; Inderpaul Singh Sehgal; Ashutosh N Aggarwal; Mandeep Garg; Biman Saikia; Digambar Behera; Arunaloke Chakrabarti
Journal:  Chest       Date:  2018-01-11       Impact factor: 9.410

Review 8.  Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity.

Authors:  Ashok Shah; Chandramani Panjabi
Journal:  Allergy Asthma Immunol Res       Date:  2016-07       Impact factor: 5.764

9.  Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.

Authors:  Karin Jonstam; Brian N Swanson; Leda P Mannent; Lars-Olaf Cardell; Nian Tian; Ying Wang; Donghui Zhang; Chunpeng Fan; Gabriele Holtappels; Jennifer D Hamilton; Annette Grabher; Neil M H Graham; Gianluca Pirozzi; Claus Bachert
Journal:  Allergy       Date:  2019-01-21       Impact factor: 13.146
  9 in total
  3 in total

1.  The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children.

Authors:  Jonathan M Gaffin; Mario Castro; Leonard B Bacharier; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol Pract       Date:  2021-12-01

2.  Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab.

Authors:  Tjeerd van der Veer; Marloes A Dallinga; Johanna P M van der Valk; Jasper H Kappen; Johannes C C M In 't Veen; Menno M van der Eerden; Gert-Jan Braunstahl
Journal:  Clin Transl Allergy       Date:  2021-12       Impact factor: 5.871

Review 3.  Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.

Authors:  Birce Sunman; Dilber Ademhan Tural; Beste Ozsezen; Nagehan Emiralioglu; Ebru Yalcin; Uğur Özçelik
Journal:  Front Pediatr       Date:  2020-10-20       Impact factor: 3.418
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.